编者按：2022 ESMO大会即将于9月9日（欧洲中部夏令时间，CEST）在法国首都巴黎凡尔赛门展览馆开幕。日前，含LBA在内的大会日程安排均已公布，我们为您悉心整理了将在会上呈现的消化肿瘤领域的重磅研究报告，以飨读者！
Mini Oral session: GI, upper digestive
1
LBA61 - HR070803 联合5-FU/LV与安慰剂联合5-FU/LV在吉西他滨难治性局部晚期或转移性胰腺癌二线治疗中的比较：一项多中心、随机、双盲、平行对照 III 期试验 （HR-IRI-APC）
-
原标题：LBA61 - HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: a multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC) -
主要作者：王理伟(Shanghai, China)
1
1296MO - PRODIGE 29-UCGI 26（NEOPAN）：一项比较化疗与福非林诺或吉西他滨治疗局部晚期胰腺癌 （LAPC）III期随机试验
-
原标题：1296MO - PRODIGE 29-UCGI 26(NEOPAN): A Phase III randomised trial comparing chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC) -
主要作者：Michel P. Ducreux(Villejuif, France)
1
-
原标题：52MO - A randomized phase II trial of durvalumab and tremelImumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naive patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC) -
主要作者：Arndt Vogel(Hannover, Germany)
1
-
原标题：53MO - Nal-IRI and 5-FU/LV Compared to 5-FU/LV in Patients With Cholangio-and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (NALIRICC – AIO-HEP-0116) 主要作者：Arndt Vogel(Hannover, Germany)
1
-
原标题：54MO - Quality of Life (QoL) and Value of Health (V-He) in advanced biliary cancers (ABC) treated with second-line Active-Symptom-Control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial -
主要作者：Angela Lamarca(Madrid, Spain)
1
1204MO-PRODIGE59-DURIGAST试验：一项评估FOLFIRI+Durvalumab和FOLFIRI+Durvalumab +Tremelimumab在晚期胃癌或胃食管交界处腺癌患者的二线治疗中应用的随机II期研究。
-
原标题：1204MO - PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab and FOLFIRI plus Durvalumab plus Tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. -
主要作者：David Tougeron(Poitiers, France)
1
1205MO - DESTINY-Gastric02的最新分析：曲妥珠单抗Deruxtecan（T-DXd）在HER2阳性（HER2 +）含曲妥珠单抗方案或之后进展的不可切除/转移性胃食管交界处（GEJ）西方患者的2期单臂试验
原标题：1205MO - Updated Analysis of DESTINY-Gastric02: a Phase 2 Single-Arm Trial of Trastuzumab Deruxtecan (T-DXd) in Western Patients (Pts) With HER2-Positive (HER2+) Unresectable/Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer Who Progressed on or After Trastuzumab-Containing Regimen
主要作者：Geoffrey Y. Ku(New York, United States of America)
Mini Oral session: GI, lower digestive
1
-
原标题：LBA26 - BREAKWATER safety lead-in (SLI): encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC) -
主要作者：Josep Tabernero(Barcelona, Spain)
1
LBA27 - MOUNTAINEER的其他分析：图卡替尼和曲妥珠单抗治疗HER2阳性mCRC的2期研究
-
原标题：LBA27 - Additional analyses of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC -
主要作者：John H. Strickler(Durham, United States of America)
1
317MO - 基于奥沙利铂的辅助化疗对老年III期结肠癌患者的疗效：12项试验的CENTCENT/IDEA汇总分析
原标题：317MO-Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: an ACCENT/IDEA pooled analysis of 12 trials
-
主要作者：Claire Gallois(Paris, France)
1
-
原标题：318MO - Circulating Tumour DNA (ctDNA) Dynamics, CEA and Sites of Recurrence for the Randomised DYNAMIC Study: Adjuvant Chemotherapy (ACT) Guided by ctDNA Analysis in Stage II Colon Cancer (CC) -
主要作者：Jeanne Tie(Melbourne, Australia)
1
319MO - 循环肿瘤DNA的真实世界监测可靠地预测切除I-III期结直肠癌患者的癌症复发
-
原标题：319MO - Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer -
主要作者：Stacey A. Cohen(Seattle, United States of America)
1
320MO-瑞戈非尼、伊匹木单抗和纳武利尤单抗在化疗耐药 MSS 转移性结直肠癌中的I期临床试验
原标题：320MO - A phase I clinical trial of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant MSS metastatic colorectal cancer (mCRC)
主要作者：Marwan G. Fakih(Duarte, United States of America)
1
-
原标题：LBA28 - Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial -
主要作者：Come Lepage(Dijon, France)
Proffered Paper session 1: GI, upper digestive
1
原标题：LBA34 - Primary results from the phase 3 LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
主要作者：Richard S. Finn(Los Angeles, United States of America)
1
-
原标题：LBA35 - Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase Ⅲ trial -
主要作者：秦叔逵(Nanjing, China)
1
原标题：LBA36 - Final Analysis of RATIONALE-301: Randomized, Phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
主要作者：Masatoshi Kudo(Osaka, Japan)
Proffered Paper session 2: GI,upper digestive
1
原标题：1203O - FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – results from the randomized phase 2 Moonlight trial of the AIO.
主要作者：Sylvie Lorenzen(Munich, Germany)
1
LBA60 - 吉西他滨+紫杉醇与单用吉西他滨治疗FOLFIRINOX失败或不耐受的转移性胰管腺癌的评估：随机III期PRODIGE65的结果–UCGI36 –GEMPAX UNICANCER研究
-
原标题：LBA60 - Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic Pancreatic Ductal Adenocarcinoma: Results of the randomized phase III PRODIGE 65 – UCGI 36 – GEMPAX UNICANCER study -
主要作者：Christelle De la Fouchardiere(Lyon, France)
1
LBA12-RLY-4008（一种高选择性 FGFR2 抑制剂）在FGFR2融合或重排、FGFR抑制剂敏感的胆管癌患者中的疗效：ReFocus试验
原标题：LBA12 - Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naive cholangiocarcinoma (CCA): ReFocus trial
主要作者：Antoine Hollebecque(Villejuif, Cedex, France)
Proffered Paper session 1: GI, lower digestive
1
LBA21 - FOLFOX/FOLFIRI联合贝伐珠单抗或帕尼单抗治疗左侧最初不可切除RAS/BRAFV600E 野生型结直肠癌肝转移患者：荷兰结直肠癌组的III期CAIRO5研究
原标题：LBA21 - FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: phase III CAIRO5 study of the Dutch Colorectal Cancer Group
主要作者：Marinde J. Bond(Utrecht, Netherlands)
1
LBA22 - FOLFIRI/Cetuximab对比FOLFIRI/Cetuximab后单独使用Cetuximab在RAS和BRAF野生型转移性结直肠癌患者一线治疗的III期研究：ERMES研究
原标题：LBA22 - Phase III study with FOLFIRI/Cetuximab versus FOLFIRI/Cetuximab followed by Cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: the ERMES Study (NCT02484833).
主要作者：Armando Orlandi(Rome, Italy)
1
314O-局部晚期结肠癌（HIPECT4）的腹腔内辅助热疗化疗：一项随机的3期研究
原标题：314O - Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (HIPECT4): a randomized,phase 3 study.
主要作者：Alvaro Arjona-Sanchez(Cordoba, Spain)
1
LBA23 - 阿维单抗比较二线标准化疗治疗转移性结直肠癌微卫星不稳定患者：SAMCO-PRODIGE 54 随机 II 期试验
原标题：LBA23 - Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): the SAMCO-PRODIGE 54 randomised phase II trial.
主要作者：Julien Taieb(Paris, France)
Proffered Paper session 2: GI, lower digestive
1
LBA24-KRYSTAL-1：阿达格拉西布（MRTX849）联合或不联合西妥昔单抗在携带KRASG12C突变的晚期结直肠癌（CRC）患者中的最新疗效和安全性
原标题：LBA24 - KRYSTAL-1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation
主要作者：Samuel J. Klempner(Boston, United States of America)
1
315O - 索托拉西与帕尼单抗联合治疗难治性KRAS G12C 突变结直肠癌：1b 期全扩充队列的安全性和有效性
-
原标题：315O - Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: safety and efficacy for phase 1b full expansion cohort -
主要作者：Yasutoshi Kuboki(Kashiwa, Japan)
1
原标题：LBA25 - FRESCO-2: A global phase 3 multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer
主要作者：N. Arvind Dasari(Houston, United States of America)
1
原标题：316O - Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study
主要作者：Scott Kopetz(Houston, United States of America)
声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。
（来源：肿瘤瞭望-消化时讯）